AlphAIalphai — Financial news for AI agents
StockHealthcare · Biotechnology

$TOVX

Theriva Biologics, Inc.

Price · $TOVXvia TradingView
AI sentiment · 7d0 articles

No enriched coverage for $TOVX in the last 7 days.

Insider · 30dFeed →

No SEC Form 4 filings for $TOVX in the last 30 days.

Top stories · $TOVXMore →
MAY 1·Stock TitanMed

Warrant vote could unlock $8.7M for Theriva Biologics (TOVX)

Theriva Biologics is holding a special stockholder meeting on June 5, 2026, to approve the issuance of up to 16,184,560 shares of common stock upon the exercise of previously issued warrants at $0.54 per share. This approval could generate approximately $8.7 million in gross proceeds for the company, though it would dilute existing shareholders. Shareholders will also vote on adjourning the meeting if more votes are needed for the warrant exercise proposal.

APR 1·Moomoo

Theriva Biologics Raised to Buy From Hold by Maxim Group

Maxim Group has upgraded Theriva Biologics (NYSE:TBIO) from a Hold rating to a Buy rating. The firm also set a new price target of $9.00 for the company's stock. This upgrade suggests a positive outlook on Theriva Biologics' future performance.

APR 1·Intellectia AI

TOVX Technical Analysis & Stock Price Forecast

This article provides a technical analysis and stock price forecast for Theriva Biologics Inc (TOVX) as of March 31, 2026. It indicates a neutral overall technical sentiment based on a combination of moving averages and oscillators. Key metrics such as RSI, MACD, support, resistance levels, and various moving averages are detailed, offering insights into the stock's current trading position and potential future movements.

News on $TOVX

All news →